Axcella Health, which is developing therapeutics and dietary products for amino acid dysregulation, announced terms for its IPO on Tuesday.
The Cambridge, MA-based company plans to raise $75 million by offering 3.6 million shares at a price range of $20 to $22. At the midpoint of the proposed range, Axcella Health would command a fully diluted market value of $546 million.
Axcella Health was founded in 2008 and plans to list on the Nasdaq under the symbol AXLA. Goldman Sachs, J.P. Morgan and SVB Leerink are the joint bookrunners on the deal. It is expected to price during the week of May 6, 2019.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.